Niagen Bioscience Reports Q2 2026 Financials, Appoints Dr. Abhijit Kale to Lead Clinical NAD+ Transition

Niagen Bioscience reported $29.8 million in Q2 2026 net sales and appointed Dr. Abhijit Kale to lead its new pharmaceutical program, signaling a strategic transition from consumer supplements toward regulated clinical development of NAD+ precursors.

Niagen Bioscience, Inc. (formerly ChromaDex, NASDAQ: NAGE) reported its Q2 2026 financial results, highlighted by $29.8 million in net sales, including $24.2 million from its Tru Niagen product, and a net income of $1.0 million.

The company appointed Abhijit Kale, Ph.D., as Senior Director of Global External Research to lead its clinical development efforts and manage external scientific collaborations.

Dr. Kale's appointment supports the company's newly launched pharmaceutical program centered on NB4168, a proprietary oral small molecule engineered to deliver elevated nicotinamide riboside (NR) exposure.

NB4168 has received Rare Pediatric Disease (RPD) designation from the FDA, which provides access to an expedited regulatory pathway and increased FDA interaction, alongside Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency (EMA).

The company has engaged Evotec as its contract research organization to conduct preclinical and IND-enabling studies for NB4168, which are scheduled to begin in Q3 2026.

The hiring of Dr. Kale and the clinical initiation of NB4168 represent a concrete pivot for Niagen Bioscience from a high-margin nutritional supplement vendor into a clinical-stage therapeutic developer.

By securing RPD and OMPD designations for its lead candidate, the company is attempting to leverage expedited regulatory pathways to validate its proprietary NAD+ delivery technologies in severe clinical indications, specifically Ataxia-Telangiectasia.

This pivot intensifies the competitive landscape for pharmaceutical-grade NAD+ therapeutics, establishing a directly funded clinical program that will compete alongside dedicated biotech developers.

The underlying consumer and telehealth business (Niagen Plus) is being utilized as a strategic source of operating cash flow to fund the capital-intensive clinical development program internally.

The initiation of preclinical and IND-enabling studies for NB4168 in collaboration with Evotec during Q3 2026, alongside initial commercial scaling of the Niagen Plus telehealth platform heading into 2027.